



CONSILIENCE

Our Experience and Capabilities
for Biotechs

July 2026

CONSILIENCE



Consilience is a boutique Life Science consultancy linking together science, strategy, and organizational context. We work as embedded advisors, supporting Pharma and Biotech clients in bringing innovative therapies to the patients most in need.

We support asset strategy from early-stage through approval and commercial launch, working with **founders and Medical, New Product Planning and Clinical leads** at Biotechs and global Pharma companies.

Our recent therapeutic area experience focuses on heme-oncology, solid tumors, rare genetic disorders, and neurology.

Technologies we're most familiar with include (multi-specific) antibodies, allogeneic and autologous cellular therapies, antibody-drug conjugates, peptide-receptor-radionuclide-therapy and -diagnostics, protein degraders, and gene therapies.

Consilience is based in Munich and was founded in 2025 by Friederike Winter and Christian Wasmer, considering principles learned during 20 years of combined Life Science consulting experience and supported by a network of accomplished leaders in the Life Science and consulting space. We uniquely combine deep scientific expertise and strategic thinking to arrive at actionable results empowering successful execution in our clients' reality.

We help you surface, shape, and communicate the full value of your assets

Area of experience	Clinical Strategy/ New Product Planning	Evidence Planning	Medical-Scientific Strategy
	Define portfolio or asset priorities and a pathway for clinical development leading to regulatory approval	Assess evidence gaps and leverage a broad range of data to support the development program	Identify where the product can address unmet medical needs and ensure relevant stakeholder engagement evidence communication
Common questions we support you with	• Which indication is most relevant for our product? What does the target product profile need to look like to be successful there? • What is the expected patient population and market size for our product in development? • Which indications are the best fit for our asset and funding situation? In which order should we move into the clinic? • Who can we partner with to maximize our product's potential, e.g., for pivotal clinical trial funding and commercialization?	• In addition to the clinical program for regulatory approval, what are the evidence requirements for other key stakeholders (e.g., HTA/ market access, physicians, patients)? • How can we best leverage real-world data and existing registries to support our strategy? • What are the upcoming competitor data readouts in our indication/ disease area and how might they affect our product in development? • Who can we collaborate with to generate relevant evidence?	• What does the current and expected future treatment landscape and patient journey look like in our disease area? What is the unmet need? Where does our product fit in? • What is the medical-scientific narrative supported by our current data? What is the aspirational narrative we want to build through future evidence? • Who are the clinical stakeholders most relevant for our product? Who are the opinion leaders in this field?

We bring a senior strategic Medical mind into the room: embedded, fractional, and as thinking partners.
We work with a small number of Biotechs at a time, in defined areas, deeply.

CONSILIENCE FOUNDERS

“We work with few clients at a time, in narrow slices, deeply – outside your org chart, no agenda beyond the work. If the fit isn't right, we'll say so.”



Dr. Friederike Winter
Managing Partner

Works across New Product Planning, Evidence Planning, Medical Strategy, and Approval Readiness for Pharma and Biotech, with a focus on oncology, rare disease, and neurology.

Over 8 years experience in advising clients, including at Prescient Healthcare Group (Medical Advisory), EY-Parthenon (Life Science Strategy), and stradoo

Therapeutic area expertise in solid tumors, heme-oncology, rare disease and neuro-immunology

MSc and DPhil (PhD) in Neuroscience from the University of Oxford, with a background in Molecular Medicine (University of Erlangen-Nürnberg)

friederike.winter@consiliencestrategy.com



Dr. Christian Wasmer
Managing Partner

Works across Clinical, New Product Planning, Medical Strategy for Pharma and Biotech clients, with a focus on oncology, rare disease, and metabolic disorders.

Over 10 years experience in advising clients; previously at Prescient Healthcare Group (Medical Advisory), Trinity Life Sciences (Strategic Advisory), Syneos Health (Advisory), and BCG

Therapeutic area expertise in oncology (heme and solid tumors), rare genetic, metabolic, and cardiovascular disorders

MSc in Physics (ETH Zurich), PhD/Doctorate (ETH Zurich) and PostDoc (Harvard Medical School) in oncology and neurology research

christian.wasmer@consiliencestrategy.com



Contact us at info@consiliencestrategy.com

www.consiliencestrategy.com